Alternatives to PPIs During 2-Week Washout for Breath Urea Test

Introduction to Alternatives

The European Society of Gastrointestinal Endoscopy recommends H2-receptor antagonists (H2RAs) such as famotidine as the preferred alternative during the 2-week PPI washout period, as they provide acid suppression without significantly affecting H. pylori bacterial load or causing false-negative breath test results 1, 2

PPIs increase gastric pH and decrease H. pylori bacterial load, particularly in the antrum, causing false-negative results in 10-40% of urea breath tests (UBTs) 1, 2
The Maastricht IV/Florence Consensus (Grade A recommendation) mandates stopping PPIs for 2 weeks before UBT, stool antigen testing, culture, histology, or rapid urease testing 1, 2

H2RAs (such as famotidine) can be substituted for PPIs during the washout period because they do not significantly affect H. pylori bacterial load and do not require discontinuation before testing 1, 2
The Maastricht guidelines specifically state that "the panel did not find it necessary to stop [H2 drugs] before testing if using citric acid" 1, 2

Patients discontinuing PPIs may experience transient upper GI symptoms due to rebound acid hypersecretion (RAHS) within the first few days, typically lasting 3-7 days 3, 4
On-demand H2RAs and over-the-counter antacids (calcium carbonate, magnesium hydroxide) should be used to manage breakthrough symptoms rather than resuming PPI therapy 5, 4
RAHS occurs due to compensatory parietal cell hyperplasia during chronic PPI therapy and takes 2-6 months to fully regress 3, 4

If stopping the PPI is not feasible due to severe symptoms or high bleeding risk, validated IgG serology can be performed instead (Grade B recommendation) 1, 2
Serology remains positive for months after H. pylori suppression or eradication and is the only test unaffected by PPIs 1, 2
However, serology cannot distinguish active from past infection and cannot confirm eradication, limiting its utility 6

The American Gastroenterological Association advises against discontinuing PPIs in patients with definite indications: Barrett's esophagus, severe erosive esophagitis, or high-risk patients requiring gastroprotection (age >60-65 years, history of upper GI bleeding, concurrent anticoagulants/multiple antithrombotics, or concurrent corticosteroids) 3, 5, 4
Patients with hypersecretory states like Zollinger-Ellison syndrome should never be de-prescribed 3
If severe persistent symptoms develop lasting more than 2 months after PPI discontinuation, this suggests a continuing indication for PPI therapy 5, 4